Details of the Drug Combinations

General Information of This Drug (ID: DMNVP8Q)

Drug Name
Tivantinib   DMNVP8Q
Synonyms
Tivantinib; 905854-02-6; ARQ-197; ARQ197; ARQ 197; Tivantinib (ARQ 197); (3R,4R)-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1H-indol-3-yl)pyrrolidine-2,5-dione; UNII-PJ4H73IL17; PJ4H73IL17; 1000873-98-2; (3R,4R)-3-(5,6-Dihydro-4H-pyrrolo(3,2,1-ij)quinolin-1-yl)-4-(1H-indol-3-yl)pyrrolidine-2,5-dione; Tivantinib [USAN:INN]; 1228508-24-4; Tivantinib; ARQ197; ARQ 197, Tivantinib; Tivantinib (ARQ-197); ARQ 197 (Tivantinib); cc-86; SCHEMBL44944; Tivantinib (JAN/USAN/INN); GTPL7948; CHEMBL2103882; CHEBI:91398; QCR-102
Indication
Disease Entry ICD 11 Status REF
Hepatocellular carcinoma 2C12.02 Phase 3 [1]
Solid tumour/cancer 2A00-2F9Z Phase 3 [2]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

13 Investigative Drug Combination(s) Consisting of This drug
Normalized Drug Combination Synergy Score
Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.
DrugCom Name DrugCom ID Component Drug Indication REF
ABT-263 + Tivantinib DCYS7C3 ABT-263 Ewing sarcoma (Cell Line: TC-71) [3]
AXL-1717 + Tivantinib DC56PLM AXL-1717 Ewing sarcoma (Cell Line: TC-71) [4]
Efaproxyn + Tivantinib DC7YEBC Efaproxyn Ewing sarcoma (Cell Line: TC-71) [4]
JQ1 + Tivantinib DCORMXU JQ1 Ewing sarcoma (Cell Line: TC-71) [4]
Nintedanib + Tivantinib DCQTACG Nintedanib Ewing sarcoma (Cell Line: TC-71) [4]
Tivantinib + MK-1775 DCDSN9I MK-1775 Ewing sarcoma (Cell Line: TC-71) [3]
Tivantinib + Panobinostat DCB9DWM Panobinostat Diffuse intrinsic pontine glioma (Cell Line: DIPG25) [3]
Tivantinib + Everolimus DCHI86A Everolimus Ewing sarcoma (Cell Line: TC-71) [3]
Tivantinib + THAPSIGARGIN DCQZU6W THAPSIGARGIN Ewing sarcoma (Cell Line: TC-71) [3]
Tivantinib + Mitomycin DC3DKX8 Mitomycin Ewing sarcoma (Cell Line: TC-71) [3]
Tivantinib + TG100801 DCYTXVB TG100801 Ewing sarcoma (Cell Line: TC-71) [3]
Tivantinib + Decitabine DC8X1PF Decitabine Ewing sarcoma (Cell Line: TC-71) [3]
Verteporfin + Tivantinib DCQL6GE Verteporfin Ewing sarcoma (Cell Line: TC-71) [4]
------------------------------------------------------------------------------------
⏷ Show the Full List of 13 DrugCom(s)
3 Clinical Trial Drug Combination(s) Consisting of This drug
DrugCom Name DrugCom ID Component Drug Indication REF
Erlotinib + Tivantinib DCOBMN1 Erlotinib Non Small Cell Lung Cancer [5]
Pazopanib + Tivantinib DC3ZEMK Pazopanib Solid Tumor [6]
Tivantinib + Leucovorin DCZJJKW Leucovorin Malignant Solid Tumour [7]
------------------------------------------------------------------------------------

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7948).
3 Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
4 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
5 ClinicalTrials.gov (NCT00777309) A Randomized Phase 2 Study of Erlotinib + ARQ 197 Versus Erlotinib + Placebo in Previously Treated Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
6 ClinicalTrials.gov (NCT01468922) Pazopanib and ARQ 197 for Advanced Solid Tumors
7 ClinicalTrials.gov (NCT01611857) Phase I/II Trial of Tivantinib With FOLFOX for the Treatment of Advanced Solid Tumors and Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction or Stomach